trpc6-in-1

TRPC6-IN-1 is an inhibitor of the Transient Receptor Potential Canonical 6 Channel (TRPC6) (EC50: 4.66 μM).

GSK 2833503A is a potent and selective TRPC6 and TRPC3 antagonist (IC50 = 3-16 nM and 21-100 nM, respectively). GSK 2833503A exhibits >63-fold selectivity over other ion channels, including other TRP channels, CaV1.2, hERG and NaV1.5. GSK 2833503A suppresses angiotensin II or endothelin-1-induced cardiac hypertrophy signaling in HEK293 cellsin vitroand in cardiomyocytes.

SAR7334 (TRCP6-IN-1) 是 TRPC6特异性抑制剂，抑制 TRPC6 电流的 IC50为 7.9 nM。

Pico145 (HC-608) 是有效的瞬时受体电位通道蛋白 1 4 5 (TRPC1 TRPC4 TRPC5) 抑制剂，在细胞中，抑制 (-)-englerin A 活化TRPC4 TRPC5 通道的IC50分别为 0.349 和 1.3 nM。

TRPC3 6-IN-1 is a highly potent and selective inhibitor that specifically blocks the activity of the canonical transient receptor channels TRPC3 and TRPC6. It exhibits a significant blocking potency against the human isoforms hTRPC3 and hTRPC6, with IC50 values of 1260 nM and 500 nM, respectively. This compound, TRPC3 6-IN-1, is particularly valuable for conducting research on chronic models of heart failure [1].

Flufenamic acid-d4 is intended for use as an internal standard for the quantification of flufenamic acid by GC- or LC-MS. Flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 3 and 9.3 µM for human COX-1 and COX-2, respectively). Flufenamic acid inhibits TNF-α-induced increases in COX-2 levels and NF-κB activation in HT-29 colon cancer cells in a concentration-dependent manner. It inhibits calcium influx induced by fMLP or A23187 in human polymorphonuclear leukocytes (PMN) with IC50 values of 29 and 14 µM, respectively. Flufenamic acid also activates various ion channels, including transient receptor potential canonical 6 (TRPC6) and the large-conductance calcium-activated potassium channel (KCa1.1). It also inhibits various ion channels, including TRPC3 and the cystic fibrosis transmembrane conductance regulator (CFTR). Flufenamic acid (20 mg kg) reduces increases in intestinal fluid secretion and intestinal barrier disruption in mice ......

Hyp9为特异性激动剂，针对瞬时受体电位阳离子通道6（TRPC6），应用于脊髓损伤（SCI）的研究。

TRPC3 6-IN-2为针对TRPC3及TRPC6的高效抑制剂，IC50分别为16 nM对TRPC3与29.8 nM对TRPC6。

Isomaltulose monohydrate 是 fMLP 抑制剂，在免疫调节中抑制 Src 激酶、ERK1 2、p38 和 AKT 磷酸化信号。它干扰 fMLP 受体 Gi 蛋白的 βγ 亚基与其下游分子的相互作用，从而抑制 fMLP 诱导的呼吸爆发。Isomaltulose monohydrate 抑制 fMLP (0.1 μM) 诱导的超氧阴离子产生 (IC50: 1.98 μM)、组织蛋白酶 G 的释放 (IC50: 2.76 μM) 和趋化性，改善中性粒细胞的过度激活，减轻炎症或组织损伤。其一系列衍生物被发现对 FSGS 相关 TRPC6 功能突变体具有抑制作用。